Ensign Group Inc header image

Ensign Group Inc

ENSG

Equity

ISIN null / Valor 3109721

NASDAQ (2025-11-21)
USD 184.99+3.15%

Ensign Group Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

The Ensign Group, Inc. operates through its independent subsidiaries, offering a comprehensive range of services across the healthcare spectrum, particularly focusing on post-acute care. This includes skilled nursing and assisted living facilities, alongside a variety of rehabilitative services such as physical, occupational, and speech therapies. Expanding beyond its traditional scope, The Ensign Group has ventured into additional post-acute care services, which encompass mobile x-ray, laboratory services, non-emergency transportation, and consulting services. These offerings are designed to meet a broad array of patient needs across several states, indicating The Ensign Group's commitment to providing a holistic approach to healthcare and rehabilitation.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (16.11.2025):

Ensign Group Inc reported its latest financial results for the fiscal year and fourth quarter of 2024, showcasing strong performance with significant increases in earnings and revenue. The company reported GAAP diluted earnings per share of $5.12 for the full year and $1.36 for the fourth quarter, alongside robust net income and revenue growth, demonstrating improved operational metrics and an optimistic outlook for 2025.

Earnings Performance

For the year ended December 31, 2024, Ensign Group Inc delivered GAAP diluted EPS of $5.12 and adjusted EPS of $5.50, while the fourth quarter figures stood at $1.36 (GAAP) and $1.49 (adjusted). Both periods experienced double-digit percentage increases compared to the respective prior periods, underlining a significant improvement in profitability.

Revenue and Net Income Growth

The company’s GAAP net income increased by 42.3% for the full year reaching $298.0 million and surged by 267.4% in the fourth quarter to $79.7 million. Adjusted net income also saw healthy gains, up 17.2% for the year and 18.9% for the quarter. Consolidated GAAP and adjusted revenues rose 14.2% and 15.5% for the year and quarter, respectively, with skilled services revenue recording solid increases as well.

Operational Enhancements

Ensign Group Inc reported improvements in occupancy, with same facilities and transitioning facilities occupancy increasing notably both on an annual and quarterly basis. The increase in managed care days and skilled revenue across these operations further highlights the company’s operational strength, driven by record clinical and financial results.

Liquidity and Forward Guidance

Maintaining robust liquidity, the company has approximately $464.6 million in cash on hand along with $572.1 million of available line-of-credit capacity. Looking ahead, management issued annual 2025 guidance projecting diluted EPS between $6.16 and $6.34 and revenue between $4.83 billion to $4.91 billion, reflecting a confident outlook built on operational fundamentals and strategic acquisitions.

Summarized from source with an LLMView Source

Key figures

25.5%1Y
98.1%3Y
165%5Y

Performance

26.3%1Y
23.5%3Y
27.4%5Y

Volatility

Market cap

10716 M

Market cap (USD)

Daily traded volume (Shares)

402,485

Daily traded volume (Shares)

1 day high/low

134.02 / 132.235

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20